Your browser doesn't support javascript.
loading
Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis.
Danieli, Patrizia; Malpasso, Giuseppe; Ciuffreda, Maria Chiara; Cervio, Elisabetta; Calvillo, Laura; Copes, Francesco; Pisano, Federica; Mura, Manuela; Kleijn, Lennaert; de Boer, Rudolf A; Viarengo, Gianluca; Rosti, Vittorio; Spinillo, Arsenio; Roccio, Marianna; Gnecchi, Massimiliano.
Afiliação
  • Danieli P; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Malpasso G; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Ciuffreda MC; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Cervio E; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Calvillo L; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Copes F; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Pisano F; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Mura M; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Kleijn L; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • de Boer RA; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Viarengo G; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Rosti V; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Spinillo A; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Roccio M; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
  • Gnecchi M; Department of Cardiothoracic and Vascular Sciences, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Laboratory of Experimental Cardiology for Cell and Molecular Therapy, Division of Clinical Immunology, Immunohematology, and Transfusion Service, Center for the Study and Cu
Stem Cells Transl Med ; 4(5): 448-58, 2015 May.
Article em En | MEDLINE | ID: mdl-25824141
ABSTRACT
The paracrine properties of human amniotic membrane-derived mesenchymal stromal cells (hAMCs) have not been fully elucidated. The goal of the present study was to elucidate whether hAMCs can exert beneficial paracrine effects on infarcted rat hearts, in particular through cardioprotection and angiogenesis. Moreover, we aimed to identify the putative active paracrine mediators. hAMCs were isolated, expanded, and characterized. In vitro, conditioned medium from hAMC (hAMC-CM) exhibited cytoprotective and proangiogenic properties. In vivo, injection of hAMC-CM into infarcted rat hearts limited the infarct size, reduced cardiomyocyte apoptosis and ventricular remodeling, and strongly promoted capillary formation at the infarct border zone. Gene array analysis led to the identification of 32 genes encoding for the secreted factors overexpressed by hAMCs. Among these, midkine and secreted protein acidic and rich in cysteine were also upregulated at the protein level. Furthermore, high amounts of several proangiogenic factors were detected in hAMC-CM by cytokine array. Our results strongly support the concept that the administration of hAMC-CM favors the repair process after acute myocardial infarction.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neovascularização Fisiológica / Células-Tronco Mesenquimais / Terapia Baseada em Transplante de Células e Tecidos / Infarto do Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Stem Cells Transl Med Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neovascularização Fisiológica / Células-Tronco Mesenquimais / Terapia Baseada em Transplante de Células e Tecidos / Infarto do Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Stem Cells Transl Med Ano de publicação: 2015 Tipo de documento: Article